8-K: Ligand Pharmaceuticals Reports Q1 2026 Results, XOMA Acquisition Update

Ligand Pharmaceuticals announced strong first quarter 2026 financial results, driven by a 56% year-over-year increase in royalty revenue, and reaffirmed its full-year guidance, incorporating the anticipated contribution from the pending acquisition of XOMA Royalty.

Summary

• Ligand Pharmaceuticals reported first quarter 2026 total revenues and income of $51.7 million, a 14% increase from $45.3 million in the prior year period.
• Royalty revenue significantly increased by 56% year-over-year, reaching $43.0 million in Q1 2026, primarily due to contributions from Travere Therapeutics' Filspari and Merck's Ohtuvayre and Capvaxive.
• Captisol sales decreased to $8.7 million in Q1 2026 from $13.5 million in Q1 2025, attributed to the timing of customer orders.
• Research and development expenses were $2.1 million in Q1 2026, a substantial decrease from $50.1 million in Q1 2025, which included a one-time $44.3 million charge.
• GAAP net loss for Q1 2026 was $13.3 million ($0.67 per share), an improvement from a net loss of $42.5 million ($2.21 per share) in Q1 2025.
• Adjusted net income grew 30% to $34.6 million ($1.63 per diluted share) in Q1 2026, compared to $26.6 million ($1.33 per diluted share) in Q1 2025.
• The company reaffirmed its 2026 full-year financial guidance, expecting adjusted earnings per diluted share between $8.50 and $9.50, and royalty revenue between $225 million and $250 million.
• Ligand announced a definitive agreement to acquire XOMA Royalty Corporation for $39.00 per share in cash, expected to close in the third quarter of 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by significant royalty revenue growth, a key drug approval, and a transformative acquisition that is expected to enhance future growth.

Positives

• Strong year-over-year royalty revenue growth of 56% in the first quarter of 2026.
• Total revenues and income increased by 14% to $51.7 million in Q1 2026.
• FDA approval of Filspari for focal segmental glomerulosclerosis (FSGS) is a significant milestone, positioning it as a key driver of long-term royalty growth.
• Adjusted net income increased by 30% to $34.6 million in Q1 2026.
• The pending acquisition of XOMA Royalty is expected to accelerate near and long-term growth, adding over 120 assets to the royalty portfolio.
• Reaffirmed 2026 full-year financial guidance, including raised expectations due to the XOMA acquisition.
• Cash, cash equivalents, and short-term investments increased to $779.4 million as of March 31, 2026.

Negatives

• Captisol sales decreased by 35.7% to $8.7 million in Q1 2026 compared to $13.5 million in Q1 2025, due to timing of customer orders.
• Non-operating expense, net, increased significantly to $41.6 million in Q1 2026 from $14.0 million in Q1 2025, primarily due to a $49.2 million non-cash loss from changes in fair value of equity-method investments.
• Reported a GAAP net loss of $13.3 million in Q1 2026, although this is an improvement from the prior year's loss.

Risks

• Ligand relies on collaborative partners for milestone payments, royalties, and other revenues, and may not receive expected revenue.
• Ligand and its partners may not be able to timely or successfully advance products in their pipeline or receive regulatory approval.
• There may not be a market for products even if successfully developed and approved.
• Ligand may not achieve its financial guidance for 2026.
• Ligand faces competition in acquiring royalties and locating suitable royalties to acquire.
• Ligand is currently dependent on a single source for Captisol, and supplier failures could cause delays or inability to meet demand.
• Ligand's partners may change their development focus or terminate agreements.
• Cyber-attacks or failures in telecommunications or IT systems could disrupt business operations.

Future Outlook

Ligand is reaffirming its 2026 full-year financial guidance, which was previously raised in connection with the announced definitive agreement to acquire XOMA. The company expects the XOMA acquisition to close in the third quarter of 2026. The guidance incorporates an anticipated partial-year contribution from XOMA, including incremental royalty revenue of approximately $25 million and anticipated cost synergies. Ligand continues to expect adjusted earnings per diluted share of approximately $8.50 to $9.50 and full-year 2026 royalty revenue in the range of $225 million to $250 million.

Management Comments

• "The first few months of 2026 have already proven to be highly productive and transformative for Ligand," said Todd Davis, CEO of Ligand.
• "In April, we announced a definitive agreement to acquire XOMA Royalty Corporation (XOMA), a highly complementary business that we expect to accelerate both near and long-term growth."
• "Upon closing, the transaction will add more than 120 commercial, clinical and preclinical-stage assets to our royalty portfolio... and meaningfully diversify Ligand across therapeutic areas, stages of development, and biopharma partners."
• "We were also pleased to see the full FDA approval of Filspari in focal segmental glomerulosclerosis (FSGS), a transformative milestone that further strengthens one of our most valuable royalty assets."

Industry Context

StockSavvy.ai notes that Ligand's strategy of acquiring royalty assets and its focus on diversifying its portfolio through acquisitions like XOMA Royalty align with broader trends in the biopharmaceutical industry where companies seek to monetize future revenue streams and gain exposure to a wider range of therapeutic areas and development stages. The FDA approval of Filspari for FSGS highlights the increasing importance of treatments for rare kidney diseases.

Comparison to Industry Standards

• Ligand's royalty revenue growth of 56% in Q1 2026 significantly outpaces the typical growth rates seen in many mature pharmaceutical segments, indicating strong performance in its niche royalty aggregation business.
• The acquisition of XOMA Royalty, adding over 120 assets, positions Ligand to compete more effectively with larger royalty aggregators and diversified biopharmaceutical companies by increasing portfolio breadth and depth.
• The focus on late-stage and commercial assets within the acquired XOMA portfolio, such as Vabysmo, Ojemda, and Miplyffa, suggests a strategic alignment with industry trends favoring assets with clearer paths to near-term revenue generation.

Legal Proceedings

• XOMA stockholders are expected to receive a Contingent Value Right (CVR) entitling them to a portion of 75% of net proceeds from certain pending litigation at XOMA.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong financial performance, acquisition of XOMA Royalty, and reaffirmed guidance. The XOMA acquisition includes a CVR for XOMA stockholders, linking their future proceeds to litigation outcomes.
• Partners: Continued collaboration on drug development and commercialization, with Ligand providing financing for late-stage programs.
• Creditors: Ligand intends to fund the XOMA acquisition through cash on hand and borrowings under its existing revolving credit facility, indicating a reliance on existing debt structures.

Next Steps

• Close the acquisition of XOMA Royalty Corporation, expected in the third quarter of 2026.
• Continue to fund high-value programs in exchange for long-term economic interests.
• Invest approximately $150 million to $250 million annually in high-value royalty assets.
• Complete enrollment of the SPARX Study for Filspari in Q2 2026.
• Submit NDA for Qtorin rapamycin for MLMs in the second half of 2026.
• Initiate Phase 3 trial of Qtorin rapamycin for cutaneous venous malformations in the second half of 2026.
• Complete enrollment of the ELAINE-3 clinical trial for Lasofoxifene in Q4 2026.

Key Dates

Recommendation

The company demonstrates robust royalty revenue growth, successful drug approvals contributing to that growth, and a strategically accretive acquisition that is expected to significantly enhance future earnings and diversify the portfolio. The reaffirmation and effective increase in full-year guidance, coupled with a strong cash position, support a strong buy recommendation.

Keywords

Ligand Pharmaceuticals, Royalty Revenue, XOMA Royalty Acquisition, Filspari, Captisol, Financial Results, SEC Filing, Form 8-K